Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation

Fig. 2

Treatment with SU11274 alters morphology of melanoma cells and their tumorigenicity. a Treatment with 1 μM SU11274 induces inhibition of cell proliferation and morphological alteration in Rel3 cells. Colonies of SU11274-treated cells appeared less scattered and formed tighter intercellular junctions. Scale bar 200 μm. b Two × 105 of untreated or SU11274-treated Rel3 cells (1 μM SU11274 for 7 days in vitro) were injected subcutaneously into the flank of immunodeficient mice. Tumor burden was significantly higher in xenografts from SU11274-treated cells, data show median tumor volume with vertical bars depicting maximum and minimum tumor volume in group, *p ≤ 0.05

Back to article page